US$ 26.30
igf 1 lr3 1mg peptide IGF-1 - IGF-1 LR3 - 1mg Peptide
Description
M.TacconeF

Research [edit] A number of agents are currently being investigated in Phase II clinical trials for IPF, including the monoclonal antibodies simtuzumab, tralokinumab, lebrikizumab and FG-3019, a lysophosphatidic acid receptor antagonist (BMS-986020)

Maresin 1 attenuates pro-inflammatory activation induced by -amyloid and stimulates its uptake

BPC-157 Body Protection Compound-157 A 15-amino-acid synthetic peptide that is among the most extensively studied repair-focused compounds in preclinical science
